Member Info for Cuddles48

Staggering valuation for a biotech. !!!!!
Loss making with only $88 million revenue. Shows how massively undervalued FAB is !!
Scottish Mortgage biotech stake spikes tenfold as Spac listing looms
Anderson and Slater’s initial stake in Ginkgo Bioworks of around £40m is now worth £450m.
by LOUKIA GYFTOPOULOU
Posted 27 AUGUST, 2021
News sponsored by:

A Scottish Mortgage holding that has already offered a tenfold return on capital is poised to offer a chunky exit as it merges with a special-purpose acquisition company (Spac).
Ginkgo Bioworks, an off-market business that engineers micro-organisms for industrial use, will enter trading in September via a merger with Soaring Eagle Acquisition Corporation, a Spac launched by former Hollywood executive Harry Sloan.
The deal, which will bring in $2.5bn (£1.82bn) in new capital, values the business at around $17.5bn, making it one of the largest Spac listings ever.
Spacs are ‘blank cheque’ vehicles that raise money through a public listing and then look to buy and take businesses public without the latter going through the rigours of the traditional initial public offering process.
Baillie Gifford managers James Anderson and Tom Slater, who manage Scottish Mortgage, have invested a total of c. £44m into just over a million shares in the MIT spin-off since an initial purchase in 2016.

ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
Those were valued at around £164m in March, but near trebled between then and June after Ginkgo announced the Spac merger. The stake is now worth around £450m, 10 times the trust’s original investment.
Baillie Gifford has also led a $775m public-investment-in-private-equity financing of Ginkgo ahead of the merger at $10 per share.
Cathy Wood’s ARK Investment Management, Putnam Investments and Counterpoint Global are among more than ten investors that also participated in the funding round.
Ginkgo, a 2.3% holding in the trust and smaller position in the asset manager’s US Growth fund, is the latest Scottish Mortgage investment to be snapped up by the cash-rich Spac vehicles, which have raised $116bn already this year following the record $83bn in 2020. It will list on the New York Stock Exchange under the ticker ‘DNA’.
At least five of the £19bn trust’s holdings are merging or have already merged with such shell companies in recent months.
Anderson and Slater declined to comment on Ginkgo’s Spac listing but have previously criticised the sector, saying many private firms that have rushed to go public in the boom of the past year are unready for the challenges of public trading.
The duo slammed the decision of two of their other holdings, ‘flying taxi’ companies Lilium and Joby, to merge with a blank-cheque company earlier this year. The latter began trading on the New York Stock Exchange this month after merging with a Reinvent Technology Partners, a Spac run by LinkedIn co-founder Reid Hoffman and Marc Pincus..
The managers said at the time they were sceptic

138 paid now.
Shows as I have repeated often that you have to buy these when stock is being offered up as the demand will eventually far outweigh supply.

I don’t think he understands the numbers for takeover deals on this sector they all start way above 9 figures.

That alone would put FAB 4 times higher than current value

A takeover is inevitable as the exit route for all the long term investors. Eurofins gets us noticed by more potential suitors.

What’s your latest prediction as we are up 8% ?

Looks like ready to rally not fall

Doubt you will get an answer on that one. !!

Oh you have upped your forecast already. To 60p you should add a zero to that and it would still be cheap.

And slowly slowly the available shares are being snapped up.

Just a matter of time before this jumps.

That might happen If only the board would get their faces in front of more of them.

And 123 bid not 115 as suggested.

Wonder why the MM won’t post the true price.

A clue to how illiquid this is price in 20,000 shares is 115/135.
This is due to the tiny free float of stock.

Oh I know I’ve seen his posts a really sad case.

Someone buying 9000 at 126.80 doesn’t agree with you Ricky.

Well Rick123 your mates in the city are willing to pay 123 and will get more and more desperate to buy as this turns much higher. With virtually no shares in free float. When it pops it will be spectacular.

In fact I see Eurofins taking this over within 6 months after they see the power of the RAMP and Optimal platforms. Got to be in it to win it.

Buy when shares are made available. Don’t dream about getting some at 50p.

I couldn’t agree with you more so where are all the new investors. Why do you think this is not being spoken about by more potential investors. And picked up on by more people.

Volumes are pathetic.

https://www.businesswire.com/news/home/20210218005767/en/Eurofins-Scientific-Announces-Acquisition-of-Beacon-Discovery-Substantially-Expanding-Its-Integrated-Drug-Discovery-Capabilities-and-Expertise

Eurofins putting a much better spin on this than FAB.

Eurofins been known to make acquisitions.

Maybe this is a prelude to an offer.

I totally agree. I am sure there is more to come. This is quite a major collaboration Eurofins have 900 labs in 50 countries with 55,000 employees.

That’s a serious spreading of the word about FAB. This puts us in front of more potential partners and I am sure more customers.

This has been down played but it’s a pretty big deal in my eyes.

This is building really nicely. I can not believe so few investors are looking at this. As it starts to grow there will be less Ans less shares available. Already the tiniest of free floats.

Once the horse has bolted people will be scrambling to buy.

Good news Eurofins are a massive company with 55,000 employees with 900 labs in 50 countries.
https://www.eurofins.com/

TUCSON, AZ / ACCESSWIRE / August 23, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, is excited to be one of 5 medical companies selected to present at the 2021 Annual Southwest Venture Madness competition. There were over 120 companies who submitted applications for this year's competition. The companies who submitted applications fell into one of five categories and only 5 finalists are selected from a specialty area. Aqualung is joined by 4 other highly qualified "medical" companies, and honored the panel found value in their company investment thesis.

Aqualung Therapeutics is an early-stage biotech company that has developed a novel therapeutic drug (ALT-100) to treat conditions driven by unchecked inflammation. Aqualung's lead indication for ALT-100 is Acute Respiratory Distress Syndrome (ARDS), a vexing condition with a 40% mortality rate but currently without FDA-approved therapies. Aqualung is finishing GMP manufacturing of ALT-100 through a global biologics contract manufacturing company and will initiate human trials at the end of this calendar year.

Another FAB Mab progressing all good for pr.

https://presentations.investormeetcompany.com/investor-meet-company/FUSION-ANTIBODIES-PLC-Final-results-presentation?bmid=e5de033c9b30

Well worth a watch very positive.

Significant value being built.

Buy the dips when you can.